Compare Wahed FTSE USA Shariah ETF (HLAL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Wahed FTSE USA Shariah ETF trades at $71.24, while Regeneron Pharmaceuticals Inc trades at $680.5 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Wahed FTSE USA Shariah ETF pays none, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| HLAL | REGN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $73.60 | $812.27 |
52-Week Low | $54.05 | $545.46 |
Market Cap | — | $70.47B |
Enterprise Value | — | $64.42B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $70.22, down 0.17% on the day, reflecting modest near-term pressure. Key financial ratios such as P/E, P/S, and ROE are not available in the current dataset, limiting fundamental visibility. A dividend of $0.02 is scheduled for June 2026, indicating a long-term income component. Trading volume and technical levels require additional market data for full context.
The outlook for HLAL hinges on upcoming financial disclosures to assess valuation and profitability. Investment opportunity lies in potential earnings growth and dividend yield, but risks include lack of current fundamental data and market volatility. Investors should await SEC filings for a clearer picture of the company's financial health.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
